Cited by 2,175PARP inhibition in cancer therapyBRCA gene mutations in cancerAdvanced Breast Cancer Therapies

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

Open access

Litton, Jennifer K., Rugo, Hope S., Ettl, Johannes, Hurvitz, Sara A., Gonçalves, Anthony, Lee, Kyung-Hun, Fehrenbacher, Louis, Yerushalmi, Rinat, Mina, Lida A., Martin, Miguel, Roché, Henri, Im, Young-Hyuck, Quek, Ruben G.W., Markova, Denka, Tudor, Iulia C., Hannah, Alison L., Eiermann, Wolfgang, Blum, Joanne L.·2018·New England Journal of Medicine

DOI 10.1056/nejmoa1802905PMC PMC10600918

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The poly(adenosine diphosphate-ribose) inhibitor talazoparib has shown antitumor activity in patients with advanced breast cancer and germline mutations in BRCA1 and BRCA2 ( BRCA1/2). METHODS: We conducted a randomized, open-label, phase 3 trial in which patients with advanced breast cancer and a germline BRCA1/2 mutation were assigned, in a 2:1 ratio, to receive talazoparib (1 mg once daily) or standard single-agent therapy of the physician's choice (capecitabine, eribulin, gemcitabine, or vinorelbine in continuous 21-day cycles). The primary end point was progression-free survival, which was assessed by blinded independent central review. RESULTS: Of the 431 patients who underwent randomization, 287 were assigned to receive talazoparib and 144 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the talazoparib group than in the standard-therapy group (8.6 months vs. 5.6 months; hazard ratio for disease progression or death, 0.54; 95% confidence interval [CI], 0.41 to 0.71; P<0.001). The interim median hazard ratio for death was 0.76 (95% CI, 0.55 to 1.06; P=0.11 [57% of projected events]). The objective response rate was higher in the talazoparib group than in the standard-therapy group (62.6% vs. 27.2%; odds ratio, 5.0; 95% CI, 2.9 to 8.8; P<0.001). Hematologic grade 3-4 adverse events (primarily anemia) occurred in 55% of the patients who received talazoparib and in 38% of the patients who received standard therapy; nonhematologic grade 3 adverse events occurred in 32% and 38% of the patients, respectively. Patient-reported outcomes favored talazoparib; significant overall improvements and significant delays in the time to clinically meaningful deterioration according to both the global health status-quality-of-life and breast symptoms scales were observed. CONCLUSIONS: Among patients with advanced breast cancer and a germline BRCA1/2 mutation, single-agent talazoparib provided a significant benefit over standard chemotherapy with respect to progression-free survival. Patient-reported outcomes were superior with talazoparib. (Funded by Medivation [Pfizer]; EMBRACA ClinicalTrials.gov number, NCT01945775 .).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1802905

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 3,013
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J. J., Takeda, S., & Pommier, Y. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,276
PARP inhibition: PARP1 and beyond
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Tutt, A. N. J., Tovey, H., Cheang, M. C. U., Kernaghan, S., Kilburn, L., Gazińska, P., Owen, J., Abraham, J., Barrett, S., Barrett-Lee, P. J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0009-7 · Cited by 909
The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
Helleday, T. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.07.001 · Cited by 895
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Murai, J., Huang, S.-Y. N., Renaud, A., Zhang, Y., Ji, J. J., Takeda, S., Morris, J., Teicher, B. A., Doroshow, J. H., & Pommier, Y. G. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0803 · Cited by 777
Repeated assessment of results in clinical trials of cancer treatment
Haybittle, J. L. (1971) · British Journal of Radiology · doi:10.1259/0007-1285-44-526-793 · Cited by 519

Flagged first, then by citations

Show all 14 references

Research works printed but not linked: 1

Turner NC, Telli ML, Rugo HS, et al. Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO). Presented at the American Society of Clinical Oncology 2017 Annual Meeting, Chicago, June 2–6, 2017. abstract.

Sorted by citations

Items 201–300 of 1,000

Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches
Dilmaç, S., & Özpolat, B. (2023) · Cancers · doi:10.3390/cancers15143642 · Cited by 96
A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer
Yuan, Y., Lee, J. S., Yost, S. E., Frankel, P. H., Ruel, C., Egelston, C. A., Guo, W., Gillece, J. D., Folkerts, M., Reining, L., et al. (2020) · The Oncologist · doi:10.1002/onco.13583 · Cited by 84
A review of current progress in triple-negative breast cancer therapy
Shen, M., Pan, H., Chen, Y., Xu, Y. H., Yang, W., & Wu, Z. (2020) · Open Medicine · doi:10.1515/med-2020-0138 · Cited by 85
CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress
Corti, C., Venetis, K., Sajjadi, E., Zattoni, L., Curigliano, G., & Fusco, N. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2054326 · Cited by 86
Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer
Page, D. B., Bear, H. D., Prabhakaran, S., Gatti-Mays, M. E., Thomas, A., Cobain, E. F., McArthur, H. L., Balko, J. M., Gameiro, S. R., Nanda, R., et al. (2019) · npj Breast Cancer · doi:10.1038/s41523-019-0130-x · Cited by 83
Self-citation
Understanding Patterns of Brain Metastasis in Triple-Negative Breast Cancer and Exploring Potential Therapeutic Targets
Lv, Y., Ma, X., Du, Y., & Feng, J. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s293685 · Cited by 85
Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer —Association With Patient and Disease Characteristics and Effect on Prognosis
Fasching, P. A., Yadav, S., Hu, C., Wunderle, M., Häberle, L., Hart, S. N., Rübner, M., Polley, E. C., Lee, K. Y., Gnanaolivu, R. D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01200 · Cited by 86
Self-citation
Mechanism of PARP inhibitor resistance and potential overcoming strategies
Fu, X., Li, P., Zhou, Q., He, R., Wang, G., Zhu, S., Bagheri, A., Kupfer, G. M., Pei, H., & Li, J. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.014 · Cited by 89
Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies
Zhu, Y., Liu, J., Park, J., Rai, P., & Zhai, R. G. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.002 · Cited by 82
The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy–Current progress and future direction
Zhao, Y., Zhang, L., Jiang, T., Long, J., Ma, Z.-Y., Lü, A., Cheng, Y., & Cao, D. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112570 · Cited by 78
Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer’s Achilles’ Heel
Caracciolo, D., Riillo, C., Martino, M. T. D., Tagliaferri, P., & Tassone, P. (2021) · Cancers · doi:10.3390/cancers13061392 · Cited by 87
Male Breast Cancer: An Updated Review of Epidemiology, Clinicopathology, and Treatment
Zheng, G., & Leone, J. P. (2022) · Journal of Oncology · doi:10.1155/2022/1734049 · Cited by 87
Hereditary breast cancer: syndromes, tumour pathology and molecular testing
Sokolova, A., Johnstone, K. J., Reed, A. E. M., Simpson, P. T., & Lakhani, S. R. (2022) · Histopathology · doi:10.1111/his.14808 · Cited by 95
Advances in Targeted Therapies for Triple-Negative Breast Cancer
McCann, K. E., Hurvitz, S. A., & McAndrew, N. P. (2019) · Drugs · doi:10.1007/s40265-019-01155-4 · Cited by 81
Self-citation
Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system ( FAERS ) database
Shu, Y., Ding, Y., He, X., Liu, Y., Wu, P., & Zhang, Q. (2022) · Cancer Medicine · doi:10.1002/cam4.5062 · Cited by 80
Novel computational and drug design strategies for inhibition of human papillomavirus-associated cervical cancer and DNA polymerase theta receptor by Apigenin derivatives
Akash, S., Bayıl, İ., Hossain, M. S., Islam, M. R., Hosen, M. E., Mekonnen, A. B., Nafidi, H., Jardan, Y. A. B., Bourhia, M., & Emran, T. B. (2023) · Scientific Reports · doi:10.1038/s41598-023-43175-x · Cited by 80
Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer
Harvey-Jones, E. J., Raghunandan, M., Robbez‐Masson, L., Magraner-Pardo, L., Alaguthurai, T., Yablonovitch, A. L., Yen, J. L., Xiao, H. F., Brough, R., Frankum, J. R., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.01.003 · Cited by 89
PARPi, BRCA, and gaps: controversies and future research
Dibitetto, D., Widmer, C. A., & Rottenberg, S. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.06.008 · Cited by 83
BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling
Shaashua, L., Ben-Shmuel, A., Pevsner-Fischer, M., Friedman, G., Levi-Galibov, O., Nandakumar, S., Barki, D., Nevo, R., Brown, L. E., Zhang, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34081-3 · Cited by 79
Breast Cancer Brain Metastasis—Overview of Disease State, Treatment Options and Future Perspectives
Watase, C., Shiino, S., Shimoi, T., Noguchi, E., Kaneda, T., Yamamoto, Y., Yonemori, K., Takayama, S., & Suto, A. (2021) · Cancers · doi:10.3390/cancers13051078 · Cited by 84
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers
Luo, L., & Keyomarsi, K. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2067527 · Cited by 79
Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review
Mohyuddin, G. R., Aziz, M., Britt, A., Lee‐Smith, W., Sun, W., Baranda, J. C., Al-Rajabi, R. M. T., Saeed, A., & Kasi, A. (2020) · BMC Cancer · doi:10.1186/s12885-020-06948-5 · Cited by 78
The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer
Spring, L. M., Bar, Y., & Isakoff, S. J. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7016 · Cited by 83
Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review
Pellegrino, B., Musolino, A., Llop‐Guevara, A., Serra, V., Silva, P. D., Hlavata, Z., Sangiolo, D., Willard-Gallo, K. E., & Solinas, C. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.10.010 · Cited by 77
The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review
Patel, M. A., Nowsheen, S., Maraboyina, S., & Xia, F. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00390-7 · Cited by 78
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors
Dieci, M. V., Miglietta, F., Griguolo, G., & Guarneri, V. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102064 · Cited by 74
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models
Herencia-Ropero, A., Llop‐Guevara, A., Staniszewska, A. D., Domènech-Vivó, J., García‐Galea, E., Moles‐Fernández, A., Pedretti, F., Domènech, H., Rodríguez, O., Guzmán, M., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01370-z · Cited by 80
Impassion132 Phase Iii Trial: Atezolizumab And Chemotherapy In Early Relapsing Metastatic Triple-Negative Breast Cancer
Cortés, J., André, F., Gonçalvès, A., Kümmel, S., Mart´n, M., Schmid, P., Schütz, F., Swain, S. M., Easton, V., Pollex, E. K., et al. (2019) · Future Oncology · doi:10.2217/fon-2019-0059 · Cited by 75
ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications
Armstrong, S. A., Schultz, C. W., Azimi-Sadjadi, A., Brody, J. R., & Pishvaian, M. J. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0208 · Cited by 78
Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets
Fang, C.-B., Wu, H.-T., Zhang, M., Liu, J., & Zhang, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00160 · Cited by 82
Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer
Huang, P., Zhou, X., Zheng, M., Yu, Y., Jin, G., & Zhang, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1263537 · Cited by 74
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing
Arun, B., Couch, F. J., Abraham, J., Tung, N., & Fasching, P. A. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02827-z · Cited by 85
BRCA mutated pancreatic cancer: A change is coming
Rosen, M. N., Goodwin, R. A., & Vickers, M. M. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i17.1943 · Cited by 75
The HER2-low revolution in breast oncology: steps forward and emerging challenges
Nicolò, E., Bielo, L. B., Curigliano, G., & Tarantino, P. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231152842 · Cited by 74
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
Lloyd, M. R., Jhaveri, K. L., Kalinsky, K. M., Bardia, A., & Wander, S. A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00935-6 · Cited by 82
Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?
Pellegrino, B., Mateo, J., Serra, V., & Balmañà, J. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000480 · Cited by 72
Immunotherapy in Triple-Negative Breast Cancer
Emens, L. A. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000497 · Cited by 71
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update
Moy, B., Rumble, R. B., Come, S. E., Davidson, N. E., Leo, A. D., Gralow, J. R., Hortobágyi, G. N., Yee, D., Smith, I. E., Chávez‐MacGregor, M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01374 · Cited by 72
U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review
Arora, S., Narayan, P., Osgood, C. L., Wedam, S. B., Prowell, T. M., Gao, J. J., Shah, M., Krol, D., Wahby, S., Royce, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2600 · Cited by 76
Updates on breast biomarkers
Najjar, S. N., & Allison, K. H. (2022) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-022-03267-x · Cited by 75
Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer
Batalini, F., Xiong, N., Tayob, N., Polak, M. M., Eismann, J., Cantley, L. C., Shapiro, G. I., Adalsteinsson, V. A., Winer, E. P., Konstantinopoulos, P. A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3045 · Cited by 73
Breast cancer brain metastasis: Current evidence and future directions
Sun, H., Xu, J., Dai, S., Ma, Y., & Sun, T. (2022) · Cancer Medicine · doi:10.1002/cam4.5021 · Cited by 77
Malignant external otitis
Babiatzki, A., & Sadé, J. (1987) · The Journal of Laryngology & Otology · doi:10.1017/s0022215100101549 · Cited by 72
Disparities in Genetic Testing and Care Among Black Women with Hereditary Breast Cancer
Reid, S., Cadiz, S., & Pal, T. (2020) · Current Breast Cancer Reports · doi:10.1007/s12609-020-00364-1 · Cited by 74
The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice
Claessens, A. K. M., Ibragimova, K. I. E., Geurts, S. M. E., Bos, M. E. M. M., Erdkamp, F., & Tjan‐Heijnen, V. C. G. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102988 · Cited by 75
The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
Wu, Z., Cui, P., Tao, H., Zhang, S., Ma, J., Liu, Z., Wang, J., Qian, Y., Chen, S., Huang, Z., et al. (2021) · Clinical Medicine Insights Oncology · doi:10.1177/1179554921996288 · Cited by 72
Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors
Garutti, M., Pelizzari, G., Bartoletti, M., Malfatti, M. C., Gerratana, L., Tell, G., & Puglisi, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143390 · Cited by 74
Developing effective combination therapy for pancreatic cancer: An overview
Miller, A. L., Garcia, P. L., & Yoon, K. J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104740 · Cited by 73
High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids
Choo, N., Ramm, S., Luu, J., Winter, J. M., Selth, L. A., Dwyer, A. R., Frydenberg, M., Grummet, J., Sandhu, S. K., Hickey, T. E., et al. (2021) · SLAS DISCOVERY · doi:10.1177/24725552211020668 · Cited by 71
The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers
Zhu, L., Liu, J., Chen, J., & Zhou, Q. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01218-8 · Cited by 71
BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer
Jacot, W., Lopez‐Crapez, E., Mollévi, C., Boissière‐Michot, F., Simony-Lafontaine, J., Ho-Pun-Cheung, A., Chartron, E., Theillet, C. G., Lemoine, A., Saffroy, R., et al. (2020) · Cancers · doi:10.3390/cancers12040828 · Cited by 66
PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities
Sim, H., Galanis, E., & Khasraw, M. (2022) · Cancers · doi:10.3390/cancers14041003 · Cited by 70
Haematologic toxicities with PARP inhibitors in cancer patients: an up‑to‑date meta‑analysis of 29 randomized controlled trials
Wang, C., & Li, J. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13349 · Cited by 66
Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe
Marmolejo, D. H., Wong, M. Y. Z., Bajalica-Lagercrantz, S., Tischkowitz, M., Balmaña, J., Patócs, A. B., Chappuis, P., Colas, C., Genuardi, M., Haanpää, M., et al. (2021) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2021.104350 · Cited by 67
Mild photothermal therapy boosts nanomedicine antitumor efficacy by disrupting DNA damage repair pathways and modulating tumor mechanics
Xiong, Y., Wang, W., Deng, Q., Zhang, Z., Wang, Q., Yong, Z., Sun, C., Yang, X., & Li, Z. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101767 · Cited by 68
A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice
Zhang, D., Baldwin, P., Leal, A. S., Carapellucci, S., Sridhar, S., & Liby, K. T. (2019) · Theranostics · doi:10.7150/thno.36281 · Cited by 68
Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation
Caulfield, S. E., Christine C. Davis, P., & Byers, K. (2019) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2019.10.2.6 · Cited by 65
Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer
Mavratzas, A., Seitz, J., Smetanay, K., Schneeweiß, A., Jäger, D., & Fremd, C. (2019) · Future Oncology · doi:10.2217/fon-2019-0468 · Cited by 65
PARP mediated DNA damage response, genomic stability and immune responses
Zong, C., Zhu, T., He, J., Huang, R., Jia, R., & Shen, J. (2021) · International Journal of Cancer · doi:10.1002/ijc.33918 · Cited by 70
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies
Russo, A. D., Incorvaia, L., Capoluongo, E., Tagliaferri, P., Gori, S., Cortesi, L., Genuardi, M., Turchetti, D., Giorgi, U. D., Maïo, M. D., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100459 · Cited by 65
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors
Schram, A. M., Colombo, N., Arrowsmith, E. R., Narayan, V., Yonemori, K., Scambia, G., Zelnak, A. B., Bauer, T. M., Jin, N. Y., Ulahannan, S. V., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.5218 · Cited by 66
Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives
Caparica, R., Lambertini, M., Ponde, N. F., Fumagalli, D., de Azambuja, E., & Piccart, M. J. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919827714 · Cited by 66
DNA damage response inhibitors: An avenue for TNBC treatment
Jin, J., Tao, Z., Cao, J., Li, T., & Hu, X. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188521 · Cited by 60
Molecular Testing in Breast Cancer
Litton, J. K., Burstein, H. J., & Turner, N. C. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_237715 · Cited by 67
Self-citation
Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations
Veneris, J. T., Matulonis, U. A., Liu, J. F., & Konstantinopoulos, P. A. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.09.021 · Cited by 62
Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer
Seligson, J. M., Patron, A. M., Berger, M. J., Harvey, R. D., & Seligson, N. D. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020966548 · Cited by 65
Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis
Schettini, F., Giudici, F., Bernocchi, O., Sirico, M., Corona, S. P., Giuliano, M., Locci, M., Paris, I., Scambia, G., Placido, S. D., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.02.035 · Cited by 65
A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status
Collins, J. M., Nordstrom, B. L., McLaurin, K. K., Dalvi, T. B., McCutcheon, S., Bennett, J. C., Murphy, B. R., Singhal, P. K., McCrea, C., Shinde, R., et al. (2021) · Oncology and Therapy · doi:10.1007/s40487-021-00162-4 · Cited by 66
PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer
Post, C., Westermann, A. M., Bosse, T., Creutzberg, C. L., & Kroep, J. R. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102973 · Cited by 64
Precision Medicine and Targeted Therapies in Breast Cancer
Greenwalt, I. T., Zaza, N. N., Das, S., & Li, B. D. �. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.08.004 · Cited by 66
Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches
Schick, J., Ritchie, R. P., & Restini, C. B. A. (2021) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223421995854 · Cited by 64
Repositioning PARP inhibitors for SARS‐CoV‐2 infection(COVID‐19); a new multi‐pronged therapy for acute respiratory distress syndrome?
Curtin, N. J., Bànyai, K., Thaventhiran, J. E. D., Quesne, J. P. C. L., Helyes, Z., & Bai, P. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15137 · Cited by 61
Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy
Peng, X., Pan, W., Jiang, F., Chen, W., Qi, Z., Peng, W., & Chen, J. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106529 · Cited by 65
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer
Im, S., Gennari, A., Park, Y. H., Kim, J. H., Jiang, Z., Gupta, S., Fadjari, T. H., Tamura, K., Mastura, M. Y., Abesamis-Tiambeng, M. L. T., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101541 · Cited by 62
Self-citation
Germline Genetic Testing for Breast Cancer Risk: The Past, Present, and Future
Yadav, S., & Couch, F. J. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238987 · Cited by 61
Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors
Garufi, G., Palazzo, A., Paris, I., Orlandi, A., Cassano, A., Tortora, G., Scambia, G., Bria, E., & Carbognin, L. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1724957 · Cited by 60
Synthetic Lethality through the Lens of Medicinal Chemistry
Myers, S. H., Ortega, J. A., & Cavalli, A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00766 · Cited by 63
Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer
Wu, H., & Chu, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020636 · Cited by 59
Therapeutic Advances in Oncology
Liu, J., Pandya, P., & Afshar, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042008 · Cited by 65
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
Vahdat, L. T., Schmid, P., Forero, A., Blackwell, K., Telli, M. L., Melisko, M., Möbus, V. J., Cortés, J., Montero, A. J., Ma, C. X., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00244-6 · Cited by 60
Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing
Terraf, P., Pareja, F. G., Brown, D. N., Ceyhan‐Birsoy, O., Misyura, M., Rana, S., O'Reilly, E. M., Carlo, M. I., Aghajanian, C. A., Liu, Y. L., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.01.006 · Cited by 61
Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia
Baer, M. R., Kogan, A. A., Bentzen, S. M., Tian, M., Lapidus, R. G., Duong, V. H., Emadi, A., Niyongere, S., O'Connell, C. L., Youngblood, B. A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3729 · Cited by 59
Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents
Martorana, F., da Silva, L. A., Sessa, C., & Colombo, I. (2022) · Cancers · doi:10.3390/cancers14040953 · Cited by 61
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer
Dent, R. A., Cescon, D. W., Bachelot, T., Jung, K. H., Shao, Z., Saji, S., Traina, T. A., Vuković, P., Mapiye, D. S., Maxwell, M. J., et al. (2023) · Future Oncology · doi:10.2217/fon-2023-0228 · Cited by 59
Detection of Pathogenic Variants With Germline Genetic Testing Using Deep Learning vs Standard Methods in Patients With Prostate Cancer and Melanoma.
AlDubayan, S., Conway, J., Camp, S., Witkowski, L., Kofman, E., Reardon, B., Han, S., Moore, N. S., Elmarakeby, H. A., Salari, K., et al. (2020) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.2020.20457 · Cited by 47
Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
Andrahennadi, S., Sami, A., Manna, M., Pauls, M., & Ahmed, S. (2021) · Current Oncology · doi:10.3390/curroncol28030168 · Cited by 60
BRCA1, BRCA2 , and Associated Cancer Risks and Management for Male Patients
Cheng, H. H., Shevach, J. W., Castro, E., Couch, F. J., Domchek, S. M., Eeles, R. A., Giri, V. N., Hall, M. J., King, M., Lin, D. W., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.2185 · Cited by 63
Optimal Systemic Treatment for Early Triple-Negative Breast Cancer
Furlanetto, J., & Loibl, S. (2020) · Breast Care · doi:10.1159/000508759 · Cited by 63
Therapies for the Treatment of Advanced/Metastatic Estrogen Receptor-Positive Breast Cancer: Current Situation and Future Directions
Rej, R. K., Roy, J., & Allu, S. R. (2024) · Cancers · doi:10.3390/cancers16030552 · Cited by 65
The paradox of cancer genes in non-malignant conditions: implications for precision medicine
Adashek, J. J., Kato, S., Lippman, S. M., & Kurzrock, R. (2020) · Genome Medicine · doi:10.1186/s13073-020-0714-y · Cited by 59
Precision medicine in breast cancer: From clinical trials to clinical practice
Crimini, E., Repetto, M., Aftimos, P. G., Botticelli, A., Marchetti, P., & Curigliano, G. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102223 · Cited by 58
Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?
Franzoi, M. A., & de Azambuja, E. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-001112 · Cited by 57
Small Molecules Targeting DNA Polymerase Theta (POLθ) as Promising Synthetic Lethal Agents for Precision Cancer Therapy
Pismataro, M. C., Astolfi, A., Barreca, M. L., Pacetti, M., Schenone, S., Bandiera, T., Carbone, A., & Massari, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02101 · Cited by 60
Targeting triple-negative breast cancer: A clinical perspective
POPOVIC, L. S., Matovina-Brko, G., Popovic, M., Punie, K., Cvetanović, A., & Lambertini, M. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.028525 · Cited by 57
Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials
Nambiar, D. K., Mishra, D., & Singh, R. P. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.028310 · Cited by 58
A systematic analysis of deep learning in genomics and histopathology for precision oncology
Unger, M., & Kather, J. N. (2024) · BMC Medical Genomics · doi:10.1186/s12920-024-01796-9 · Cited by 62
PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation
Michmerhuizen, A. R., Pesch, A. M., Moubadder, L., Chandler, B. C., Wilder-Romans, K., Cameron, M., Olsen, E. C., Thomas, D. G., Zhang, A., Hirsh, N. H., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0520 · Cited by 56
Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors
Paulet, L., Trécourt, A., Leary, A. F., Péron, J., Descôtes, F., Devouassoux‐Shisheboran, M., Leroy, K., You, B., & Lopez, J. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.01.037 · Cited by 57
Early stage triple negative breast cancer: Management and future directions
Chaudhary, L. N. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.05.006 · Cited by 57
Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study
Turner, N. C., Balmañà, J., Poncet, C., Goulioti, T., Tryfonidis, K., Honkoop, A. H., Zoppoli, G. M., Razis, E. D., Jóhannsson, Ó. Þ., Colleoni, M. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0310 · Cited by 55

Authors: Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., Roché, H., Im, Y.-H., Quek, R. G. W., Markova, D., Tudor, I. C., Hannah, A. L., Eiermann, W., & Blum, J. L.
Affiliations: Kaiser Permanente (US)
From the University of Texas M.D. Anderson Cancer Center, Houston (J.K.L.), and the Texas Oncology–Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas (J.L.B.) — both in Texas; University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center (H.S.R.), and Pfizer (R.G.W.Q., D.M., I.C.T., A.L.H.), San Francisco, University of California, Los Angeles, Los Angeles (S.A.H.), and Kaiser Permanente, Northern California, Vallejo (L.F.) — all in California; the...
ORCID: Litton, Jennifer K.
Rugo, Hope S.
Ettl, Johannes
Hurvitz, Sara A.
Lee, Kyung-Hun
Fehrenbacher, Louis
Yerushalmi, Rinat
Mina, Lida A.
Im, Young-Hyuck
Quek, Ruben G.W.
Tudor, Iulia C.
Blum, Joanne L.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2018-08-23
Volume: 379
Issue: 8
Pages: 753-763
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1802905
PMC: PMC10600918
OpenAlex: W2886477543
Cited by: 2,175
References: 14
Citations by year: 2026: 195 · 2025: 241 · 2024: 254 · 2023: 312 · 2022: 356 · 2021: 319 · 2020: 280 · 2019: 195 · 2018: 20
FWCI: 76.58
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
mediaTUM (Technical University of Munich) (submittedVersion)
Funders: Pfizer
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords: PARP inhibitors, advanced breast cancer, germline BRCA1 mutation, germline BRCA2 mutation, progression-free survival, objective response rate, hematologic adverse events, anemia, patient-reported outcomes, quality of life, single-agent chemotherapy, capecitabine, eribulin, gemcitabine, vinorelbine, PARP inhibitor resistance, PARP inhibitor combination therapy
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, Patient Reported Outcome Measures, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Middle Aged, Phthalazines, Quality of Life, Survival Analysis, Germ-Line Mutation, Disease-Free Survival, Genes, BRCA1, Genes, BRCA2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks